Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica, São Paulo, SP, Brasil.
Departamento de Obesidade, Sociedade Brasileira de Endocrinologia e Metabologia, São Paulo, SP, Brasil.
Arch Endocrinol Metab. 2023 Aug 16;67(4):e230174. doi: 10.20945/2359-4292-2023-0174.
Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term "weight loss drugs" to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as "medications to treat obesity" or "anti-obesity medications" conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care.
肥胖症的治疗往往不足，部分原因是该疾病及其治疗方法存在污名化现象。用“减肥药”来指代治疗肥胖症的药物可能会加剧这种污名化，让人觉得任何想要减肥的人都可以使用这些药物，而且只在积极减肥阶段短期使用就足够了。相反，使用“治疗肥胖症的药物”或“抗肥胖症药物”等术语传达了这样一种理念，即治疗针对的是疾病本身，而不是症状。巴西肥胖与代谢综合征研究学会（ABESO）和巴西内分泌学会（SBEM）联合发布这份声明，旨在提醒媒体、医疗保健专业人员和科学界注意语言使用的重要性，目的是改善肥胖症的治疗。
